Abstract
13-cis retinoic acid + (OH)2 vitamin D3 + low-dose 6-thioguanine and cytarabine were tested in 26 patients with acute myeloid leukemia (AML) and in 4 patients with myelodysplastic syndrome (MDS) (median age 72.5), ineligible for standard chemotherapy. The response rate was 50%, with 27% complete remission. The median survival of the whole group and responders was 7.5 (1-47+) and 16.5 months (3.5-47+), respectively.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Calcitriol / administration & dosage
-
Cytarabine / administration & dosage
-
Disease Progression
-
Female
-
Humans
-
Isotretinoin / administration & dosage
-
Leukemia, Myeloid / drug therapy*
-
Male
-
Middle Aged
-
Myelodysplastic Syndromes / drug therapy*
-
Thioguanine / administration & dosage
Substances
-
Cytarabine
-
Isotretinoin
-
Thioguanine
-
Calcitriol